Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2023 08:00 ET | Source: Imunon, Inc.

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J., May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
May 11, 2023 08:00 ET | Source: Imunon, Inc.

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT...
May 04, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
April 19, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001

Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE...
March 30, 2023 08:00 ET | Source: Imunon, Inc.

IMUNON Reports 2022 Financial Results and Provides Business Update

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused...
March 23, 2023 08:30 ET | Source: Imunon, Inc.

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation...
March 22, 2023 08:00 ET | Source: Imunon, Inc.

IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023

Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J., March 22, 2023 ...
March 21, 2023 16:30 ET | Source: Imunon, Inc.

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today...
March 15, 2023 14:00 ET | Source: Imunon, Inc.

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based...
March 01, 2023 08:45 ET | Source: Imunon, Inc.

IMUNON CEO Issues Letter to Shareholders

Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision LAWRENCEVILLE, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage...